- Home
- AIRS vs ATYR Comparison
AIRS vs ATYR Comparison
Compare AIRS & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- ATYR
- Stock Information
- Founded
- AIRS 2012
- ATYR 2005
- Country
- AIRS United States
- ATYR United States
- Employees
- AIRS N/A
- ATYR N/A
- Industry
- AIRS Medical/Nursing Services
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIRS Health Care
- ATYR Health Care
- Exchange
- AIRS Nasdaq
- ATYR Nasdaq
- Market Cap
- AIRS 333.7M
- ATYR 327.0M
- IPO Year
- AIRS 2021
- ATYR 2015
- Fundamental
- Price
- AIRS $2.15
- ATYR $2.95
- Analyst Decision
- AIRS Hold
- ATYR Strong Buy
- Analyst Count
- AIRS 3
- ATYR 6
- Target Price
- AIRS $3.75
- ATYR $18.60
- AVG Volume (30 Days)
- AIRS 374.4K
- ATYR 1.6M
- Earning Date
- AIRS 03-14-2025
- ATYR 03-13-2025
- Dividend Yield
- AIRS N/A
- ATYR N/A
- EPS Growth
- AIRS N/A
- ATYR N/A
- EPS
- AIRS N/A
- ATYR N/A
- Revenue
- AIRS $180,350,000.00
- ATYR $235,000.00
- Revenue This Year
- AIRS N/A
- ATYR $1,387.23
- Revenue Next Year
- AIRS $5.63
- ATYR $873.22
- P/E Ratio
- AIRS N/A
- ATYR N/A
- Revenue Growth
- AIRS N/A
- ATYR N/A
- 52 Week Low
- AIRS $2.05
- ATYR $1.42
- 52 Week High
- AIRS $9.20
- ATYR $4.66
- Technical
- Relative Strength Index (RSI)
- AIRS 27.39
- ATYR 36.55
- Support Level
- AIRS $2.58
- ATYR $3.20
- Resistance Level
- AIRS $2.91
- ATYR $3.94
- Average True Range (ATR)
- AIRS 0.33
- ATYR 0.27
- MACD
- AIRS 0.01
- ATYR -0.08
- Stochastic Oscillator
- AIRS 19.33
- ATYR 2.94
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.